24
19
1
49
2
2
2c
1b
1d
18
33
82
1d
2 29
1d
25
Corey J. Langer, M.D.
78
82
Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-138
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 10th Floor, South Pavilion
16 Office #10-138
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 215-615-5121
32 Fax: 215-615-5122
35 Lab: CP 215-806-6152
18
a7
12
32 Fax: 215-615-5122
35 Lab: CP 215-806-6152
18
13
Education:
21 e B.A./M.D. 36 (Liberal Arts and Medicine 6 year Combined) c
2a Boston University, 1981.
c
3
3
3
3
8d
Permanent link21 e B.A./M.D. 36 (Liberal Arts and Medicine 6 year Combined) c
2a Boston University, 1981.
c
2 29
21
1e
1d
24
5e
38 Role of targeted agents in oncogene-driven NSCLC
1e New strategies in SCLC
7b Unique combined modality strategies integrating radiation and systemic treatment in LA-NSCLC and limited stage SCLC
68 Underserved populations, including older patients and those with compromised performance status.
44 Novel therapeutic venues in thoracic and head and neck cancer
65
1a 29
27
Description of Research Expertise
42 Maturing role of immunotherapy in advanced NSCLC.38 Role of targeted agents in oncogene-driven NSCLC
1e New strategies in SCLC
7b Unique combined modality strategies integrating radiation and systemic treatment in LA-NSCLC and limited stage SCLC
68 Underserved populations, including older patients and those with compromised performance status.
44 Novel therapeutic venues in thoracic and head and neck cancer
65
Description of Clinical Expertise
55 Thoracic Medical Oncology with focus on NSCLC, SCLC, and Mesothelioma1a 29
23
1d1 Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ.: Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy. Am J Clin Oncol Nov 2025.
1fa Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT.: Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911. Int J Radiat Oncol Biol Phys 124: 50-60, Jul 2025.
19f Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S.: Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer Jun 2025.
1c2 Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L.: Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. JTO Clin Res Rep 6: 100851, May 2025.
23e Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME.: Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer 203, May 2025.
1a4 Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C.: Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy. Clin Lung Cancer 26(2): 158-163.e2, March 2025.
17c Stalker M, Walker SL, Lebow E, Pai EL, Watts A, Hwang WT, Banihashemi A, Anderson E, Roshkovan L, Katz SI, Litzky L, Haas AR, Singhal S, Langer CJ, Cengel K, Marmarelis ME.: Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy. JTO Clin Res Rep 6: 100823, Mar 2025.
12e Stalker M, Marmarelis M, Langer C, Cohen RB, Singh A, Aggarwal C, Sun L.: Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC. Clin Lung Cancer 26(2): 124-130.e1, March 2025.
196 Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ; LUNAR study investigators.: The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study. Lung Cancer 2025.
2c
7
1d
1f
Selected Publications
17b Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME.: Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC). Lung Cancer March 2026.1d1 Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ.: Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy. Am J Clin Oncol Nov 2025.
1fa Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT.: Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911. Int J Radiat Oncol Biol Phys 124: 50-60, Jul 2025.
19f Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S.: Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer Jun 2025.
1c2 Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L.: Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. JTO Clin Res Rep 6: 100851, May 2025.
23e Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME.: Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis. Lung Cancer 203, May 2025.
1a4 Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C.: Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy. Clin Lung Cancer 26(2): 158-163.e2, March 2025.
17c Stalker M, Walker SL, Lebow E, Pai EL, Watts A, Hwang WT, Banihashemi A, Anderson E, Roshkovan L, Katz SI, Litzky L, Haas AR, Singhal S, Langer CJ, Cengel K, Marmarelis ME.: Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy. JTO Clin Res Rep 6: 100823, Mar 2025.
12e Stalker M, Marmarelis M, Langer C, Cohen RB, Singh A, Aggarwal C, Sun L.: Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC. Clin Lung Cancer 26(2): 124-130.e1, March 2025.
196 Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ; LUNAR study investigators.: The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study. Lung Cancer 2025.
2c
44
23
Back to Top
1b
1d
18